Natera (NTRA) UBS Global Healthcare Conference 2024 summary

Financial and operational performance

• Q3 revenue reached $430 million, up 63% year-on-year, with gross margins rising to 61% from the 40s and $35 million in cash generated, marking a significant milestone toward cash flow positivity.

• Strong volume growth, especially in Signatera Clinical Units, with momentum evident both sequentially and year-over-year.

• Women's health and organ health businesses continued robust performance, with retention of acquired Invitae units contributing to the baseline for future growth.

• True-up revenue adjustments have been significant due to rising ASPs, but are expected to decline as accruals align with actual cash flows.

• Commercial operations have remained efficient, with a stable sales rep base delivering consistent unit growth.

Product and clinical data updates

• Three-year overall survival data from the Galaxy study showed Signatera's predictive value for survival and chemotherapy benefit, with 100% survival in patients clearing ctDNA.

• Upcoming data readouts at ASCO GI in January include the ALTAIR and CALGB 702 studies, the latter focusing on Celebrex in stage 3 colorectal cancer.

• Additional interventional trial readouts, including IMvigor011, are anticipated in 2025, with timing dependent on external partners.

• Submissions to MolDX may yield new reimbursed indications in 2025, though most current volume is already within reimbursed tumor types.

2025 outlook and strategic priorities

• Sequential unit growth for Signatera is expected to continue at 8,000–10,000 per quarter, with women's health growth normalized after backing out the Invitae acquisition bump.

• Aggregate unit growth in 2025 should be comparable to 2024, excluding the one-time Invitae effect.

• ASP for Signatera reached $1,050 in Q3, with modest improvement expected in 2025, driven by increased Medicare Advantage coverage and potential state biomarker law impacts in the second half.

• Women's health ASPs are expected to remain flat or improve slightly, despite typical industry erosion trends.

• Focus remains on meeting patient needs and maintaining self-sustaining operations, rather than maximizing near-term EBITDA.